

## CDC Updates Strategies for Optimizing Supply of N95 Respirators – September 16, 2021


### Summary of Recent Changes

#### For Contingency Capacity Strategies:

Beyond anticipated shortages, added that increased feasibility and practicality may also be considered in decisions to implement extended use for healthcare personnel (HCP) who re sequentially caring for a large volume of patients with suspected or confirmed SARS-CoV-2, including those cohorted in a SARSCoV-2 unit, those placed in quarantine, and residents on units impacted during a SARS-CoV-2 outbreak.

#### For Crisis Capacity Strategies:

- Added information about FDA’s reassurance of the Emergency Use Authorization (EUA) in July 2021. FDA removed filtering facepiece respirators that are NIOSH-approved but have since passed the manufacturers’ recommended shelf life and removed decontaminated respirators from the scope of authorization.
- Added clarification and example scenarios for limited re-use.
- Deleted the strategy, to exclude HCP at increased risk for severe illness from SARS-CoV-2 infection from contact with patients with known or suspected SARS-CoV-2 infection



<https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirators-strategy/index.html>

This work is licensed under the Creative Commons Attribution-NoDerivatives 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nd/4.0/>

*This policy and procedure is not intended to replace the informed judgment of individual physicians, nurses or other clinicians nor is it intended as a statement of prevailing community standards or minimum standards of practice. It is a suggested method and technique for achieving optimal health care, not a minimum standard below which residents necessarily would be placed at risk.*